Target intelligence / Profile preview

Guanidinoacetate N-methyltransferase (GAMT)

Target
GAMT
Molecular classification
Enzyme, Transferase, Methyltransferase
01

Overview

Guanidinoacetate N-methyltransferase is a key enzyme in the biosynthesis of creatine, catalyzing the transfer of a methyl group from S-adenosylmethionine to guanidinoacetate to produce creatine, a molecule critical for energy storage and utilization in cells, especially neurons and myocytes[1][2][3]. Its deficiency leads to a rare but treatable neurometabolic disorder characterized by mental retardation, movement disorder, seizures, and muscle hypotonia; creatine supplementation can ameliorate many symptoms[3][5]. GAMT is predominantly expressed in the liver, brain, and certain glial cells (notably oligodendrocytes), and supports cellular energy metabolism and neurodevelopment. GAMT's function links methyl group metabolism to ATP buffering, highlighting its fundamental biological importance[1][4].

Other names
GAMTGuanidinoacetate methyltransferaseGuanidinoacetate transmethylaseMethionine-guanidinoacetic transmethylaseGA methylpherasePIG2TP53I2HEL-S-20CCDS2Epididymis secretory protein Li 20Guanidoacetate methyltransferase
02

Mechanism of action

Creatine supplementation: supplies missing creatine, bypassing the metabolic block caused by GAMT deficiency

03

Biological functions

Creatine biosynthesis (final step: conversion of guanidinoacetate to creatine)Energy homeostasis (buffering ATP in muscle and brain)Fatty acid oxidation activation (cellular energy source under stress)Neurodevelopment (GAMT and creatine are important for normal neuronal function)
04

Disease associations

Neurological disorders (GAMT deficiency leads to cerebral creatine deficiency syndrome with intellectual disability, epilepsy, and movement disorder)Muscular hypotonia (creatine deficiency impairs muscle function)Cardiovascular implications (GAMT deficiency studied in cardiac function and metabolism)Potential other metabolic diseases due to creatine metabolism impairment
05

Safety considerations

Creatine supplementation generally considered safe, but high guanidinoacetate levels may be neurotoxicTherapeutic challenge: must differentiate between symptoms caused by creatine deficiency vs. guanidinoacetate excess
06

Interacting drugs

Creatine
07

Biomarkers

Low creatine in brain and muscle (biochemical diagnosis of GAMT deficiency)Elevated guanidinoacetate (secondary substrate accumulation)

Beyond the preview

Go deeper on Guanidinoacetate N-methyltransferase (GAMT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guanidinoacetate N-methyltransferase (GAMT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call